Engitix

Engitix is using its groundbreaking human extracellular matrix (ECM) platform to develop new and better therapies for treating advanced fibrosis and solid tumors, with an initial focus on gastrointestinal diseases. The use of more physiologically relevant in vitro human models is transforming the ability to identify new targets, develop more advanced treatments, and enable more accurate prediction of the efficacy of candidate therapeutic drugs.